Semaglutide-assisted weight loss may lessen the heart and blood vessel burden, possibly lowering some cardiovascular risks
Advertisement Article continues below this ad Guest opinions in Open Forum and Insight are produced by writers with expertise, personal experience or original insights on a subject of interest to our readers
Several alternatives are available, including other GLP-1 receptor agonists with different side effect profiles, DPP-4 inhibitors, SGLT2 inhibitors, or insulin therapy for diabetes management
1 The oral formulation, recently launched as a highly anticipated weight-loss treatment, will be available in 1.5 mg, 4 mg, 9 mg, and 25 mg strengths, while the injectable Wegovy will be offered in doses ranging from 0.25 mg to 2.4 mg
"Everybody thinks it's Ozempic," Clarkson told Goldberg
Differentiation of human adipose-derived mesenchymal stem cell into insulin-producing cells: An in vitro study